Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
Lineage Cell Therapeutics, Inc. (BTX)
|
Add to portfolio |
|
|
|
| Price: |
$4.51
| | Metrics |
| OS: |
175.0
|
M
| |
-31
|
% ROE
|
| Market cap: |
$789
|
M
| |
-361
|
% ROIC
|
|
Net cash:
|
$45.9
|
M
| |
$0.26
|
per share
|
|
EV:
|
$743
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($23.0)
|
M
| |
|
|
|
EBIT
|
($23.6)
|
M
| |
|
|
| EPS |
($0.13)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 13.4 | 1.1 | 1.8 | 3.5 | 5.0 | 7.2 | 5.7 | 4.5 |
| Revenue growth | 1093.5% | -38.7% | -48.1% | -29.5% | -30.5% | 26.4% | 25.4% | -13.7% |
| Cost of goods sold | 0.7 | 1.4 | 0.4 | 0.4 | 0.3 | 7.2 | 5.7 | 4.5 |
| Gross profit | 12.6 | -0.3 | 1.4 | 3.1 | 4.7 | 0.0 | 0.0 | 0.0 |
| Gross margin | 94.6% | -27.3% | 78.9% | 88.3% | 93.9% | 0.0% | 0.0% | 0.0% |
| Sales and marketing | | | | | | 2.4 | 1.2 | 0.3 |
| Research and development | 14.0 | 33.9 | 12.3 | 17.9 | 21.0 | | | |
| General and administrative | 22.5 | 18.2 | 15.6 | 24.0 | 24.7 | 9.2 | 4.3 | 3.9 |
| EBITA | -22.4 | -49.0 | -25.2 | -36.9 | -38.8 | -18.6 | -10.9 | -8.5 |
| EBITA margin | -167.4% | -4375.1% | -1381.8% | -1049.2% | -777.9% | -259.4% | -192.0% | -187.2% |
| Amortization of intangibles | 0.1 | 0.2 | 1.2 | 2.0 | 2.2 | 0.2 | 0.2 | 0.2 |
| EBIT | -22.5 | -49.2 | -26.4 | -38.9 | -41.0 | -18.8 | -11.1 | -8.7 |
| EBIT margin | -168.5% | -4393.8% | -1448.4% | -1106.0% | -821.9% | -262.7% | -196.2% | -192.6% |
| Pre-tax income | -25.8 | -43.3 | -21.9 | -19.2 | -47.1 | -19.4 | -11.2 | -8.7 |
| Income taxes | 0.5 | -0.3 | -1.2 | -7.4 | -0.3 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.6% | 5.7% | 38.5% | 0.7% | 0.0% | 0.0% | 0.0% |
| Net income | -26.3 | -43.0 | -20.6 | -11.7 | -46.0 | -19.4 | -11.2 | -8.7 |
| Net margin | -196.6% | -3841.0% | -1130.8% | -333.1% | -922.0% | -270.1% | -196.7% | -193.0% |
| |
| Diluted EPS | ($0.15) | ($0.26) | ($0.14) | ($0.08) | ($0.36) | ($0.64) | ($0.42) | ($0.42) |
| Shares outstanding (diluted) | 169.8 | 164.5 | 150.0 | 145.5 | 126.9 | 30.2 | 26.5 | 21.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|